Edition:
India

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

12.28CNY
14 Dec 2018
Change (% chg)

¥-0.42 (-3.31%)
Prev Close
¥12.70
Open
¥12.78
Day's High
¥12.90
Day's Low
¥12.22
Volume
19,054,131
Avg. Vol
17,046,224
52-wk High
¥32.83
52-wk Low
¥10.62

Latest Key Developments (Source: Significant Developments)

U.S. FDA Releases Warning Letter To Zhejiang Huahai Pharmaceutical
Wednesday, 12 Dec 2018 

Dec 11 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::U.S. FDA RELEASED WARNING LETTER ISSUED TO ZHEJIANG HUAHAI PHARMACEUTICAL, MANUFACTURER OF ACTIVE PHARMACEUTICAL INGREDIENT FOUND IN VALSARTAN.FDA- WARNING LETTER OUTLINES SEVERAL MANUFACTURING VIOLATIONS AT ZHP’S CHUANNAN FACILITY, INCLUDING IMPURITY CONTROL, CHANGE CONTROL & CROSS CONTAMINATION.  Full Article

Zhejiang Huahai Pharmaceutical Clarifies Reports Related To Sandoz's Product Recall
Friday, 9 Nov 2018 

Nov 10 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS IT CLARIFIES ONLINE REPORTS ON HUAHAI BEING INVOLVED IN MANUFACTURING RAW MATERIALS CONTAINING NDEA IMPURITIES THAT PROMPTED SANDOZ TO RECALL A BATCH OF ITS LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE TABLETS.SAYS THE REPORTS WERE VAGUE AND DID NOT CLEARLY STATE THE FACTS,WHICH HAS MISLED INVESTORS.  Full Article

Zhejiang Huahai Pharmaceutical Says 9-Month Net Profit Down 47.4 Percent Y/Y
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS 9-MONTH NET PROFIT DOWN 47.4 PERCENT Y/Y.  Full Article

Zhejiang Huahai Pharma's Controlling Shareholder Adds Holdings
Wednesday, 10 Oct 2018 

Oct 10 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS CONTROLLING SHAREHOLDER HAS BOUGHT 800,000 SHARES, OR 0.07 PERCENT STAKE, IN THE COMPANY ON OCT 10.SAYS IT HAS HIRED DUANE MORRIS LLP TO REPRESENT THE COMPANY IN LEGAL CASES INVOLVING VALSARTAN ISSUES.  Full Article

Zhejiang Huahai Pharma Sees temporary Impact From Valsartan Issue, Won't affect Long-term Strategy
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS JAN-AUG SALES OF PRODUCTS AFFECTED BY U.S. AND EUROPE MOVE ABOUT 430 MILLION YUAN ($62.12 million), ACCOUNTED FOR 13 PERCENT OF TOTAL REVENUES.SAYS VALSARTAN ISSUES CAUSES TEMPORARY EFFECTS ON THE COMPANY, WILL NOT CHANGE ITS LONG-TERM STRATEGIC DEVELOPMENT PLAN.  Full Article

Zhejiang Huahai Pharma Sees Impacts On Valsartan Exports Following U.S, European Actions
Sunday, 7 Oct 2018 

Oct 7 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS DECISIONS BY U.S. FDA, EUROPEAN AUTHORITIES WILL CAUSE IMPACT ON ITS VALSARTAN INGREDIENTS EXPORTS.SAYS IT FACES RISKS INCLUDING BEING SUED BY CLIENTS, FURTHER ACTIONS BY THE EUROPEAN AUTHORITIES.SAYS IT, UNITS SUED BY U.S. CONSUMERS IN SEVERAL CASES IN NEW YORK, ILLINOIS DUE TO ITS VALSARTAN ISSUE.SAYS IT WILL HOLD INVESTORS CONFERENCE ON OCT 8.  Full Article

Health Canada Finds Zhejiang Huahai Pharmaceuticals Site Non-Compliant With Requirements For Manufacture Of Drug Ingredients
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Health Canada::HEALTH CANADA - FINDS ZHEJIANG HUAHAI PHARMACEUTICALS SITE NON-COMPLIANT WITH REQUIREMENTS FOR MANUFACTURE OF DRUG INGREDIENTS.HEALTH CANADA - DECISION BASED ON REVIEW OF INFORMATION FROM RECENT INSPECTION CONDUCTED BY U.S. FOOD AND DRUG ADMINISTRATION.HEALTH CANADA- NON-COMPLIANT RATING INCLUDES ASSESSING POSSIBLE EFFECTS ON DRUG SUPPLY AND WHETHER MEASURES MAY BE NEEDED TO MITIGATE SUPPLY CONCERNS.HEALTH CANADA - NO PRODUCTS ARE BEING RECALLED AT THIS TIME.HEALTH CANADA- NON-COMPLIANT RATING DOES NOT NECESSARILY INDICATE A PRODUCT SAFETY CONCERN.  Full Article

Zhejiang Huahai Pharma's Controlling Shareholder To Increase Holdings In The Company
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS CONTROLLING SHAREHOLDER PLANS TO INCREASE UP TO 5 MILLION SHARES IN THE COMPANY WITHIN SIX MONTHS.  Full Article

Zhejiang Huahai Pharmaceutical To Recall Valsartan-Containing Pharmaceutical Products From U.S. Consumers
Thursday, 19 Jul 2018 

July 19 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS IT DECIDES TO RECALL VALSARTAN-CONTAINING PHARMACEUTICAL PRODUCTS FROM CONSUMERS IN THE U.S. AND TO HALT ITS SUPPLY OF PRODUCTS TO THE U.S..SAYS ITS U.S. UNIT IS CONTACTING DISTRIBUTORS AND CUSTOMERS FOR PRODUCT RETURN.SAYS IT CANNOT ACCURATELY ESTIMATE THE LOSS CAUSED BY PRODUCT RECALL AT THIS STAGE, BUT WILL TRY TO MINIMIZE THE LOSSES.  Full Article

FDA Announces Voluntary Recall Of Several Medicines Containing Valsartan Following Detection Of An Impurity
Saturday, 14 Jul 2018 

July 13 (Reuters) - Teva Pharmaceutical Industries Ltd ::FDA ANNOUNCES VOLUNTARY RECALL OF SEVERAL MEDICINES CONTAINING VALSARTAN FOLLOWING DETECTION OF AN IMPURITY.FDA SAYS VOLUNTARY RECALL DUE TO AN IMPURITY, N-NITROSODIMETHYLAMINE (NDMA), WHICH WAS FOUND IN THE RECALLED PRODUCTS.FDA SAYS PRESENCE OF NDMA IN RECALLED PRODUCTS WAS UNEXPECTED & IS THOUGHT TO BE RELATED TO CHANGES IN THE WAY THE ACTIVE SUBSTANCE WAS MANUFACTURED.FDA SAYS NOT ALL PRODUCTS CONTAINING VALSARTAN ARE BEING RECALLED.FDA SAYS TEVA PHARMACEUTICALS, MAJOR PHARMACEUTICALS, SOLCO HEALTHCARE RECALLING NON-EXPIRED PRODUCTS CONTAINING VALSARTAN SUPPLIED BY THIRD-PARTY.  Full Article

Photo

EU places China's Zhejiang Huahai under increased supervision

European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.